Published in Cell Cycle on May 15, 2012
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci (2013) 0.95
YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One (2014) 0.90
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget (2016) 0.86
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest (2015) 0.84
ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res (2013) 0.83
A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget (2015) 0.80
Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer. J Ovarian Res (2016) 0.79
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy. Oncotarget (2017) 0.78
Selenium-enriched polysaccharides from Pyracantha fortuneana (Se-PFPs) inhibit the growth and invasive potential of ovarian cancer cells through inhibiting β-catenin signaling. Oncotarget (2016) 0.76
Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer. Sci Rep (2016) 0.76
Ovarian cancer stem cells: still an elusive entity? Mol Cancer (2017) 0.75
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget (2016) 0.75
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells (2007) 2.39
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol (2002) 2.27
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Adiponectin and hypertension in normal-weight and obese children. Am J Hypertens (2012) 2.09
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev (2011) 1.63
Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol (2012) 1.63
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62
Improved extraction of vegetable oils under high-intensity ultrasound and/or microwaves. Ultrason Sonochem (2007) 1.59
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ (2010) 1.55
Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol (2004) 1.52
Molecular epidemiology of norovirus infections in sporadic cases of viral gastroenteritis among children in Northern Italy. J Med Virol (2006) 1.47
Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest (2004) 1.47
Clinical and mutational spectrum of Mowat-Wilson syndrome. Eur J Med Genet (2005) 1.46
A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood (2002) 1.45
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle (2012) 1.44
Unleashing Chk1 in cancer therapy. Cell Cycle (2011) 1.44
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not. Cancer Biol Ther (2006) 1.43
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
Estrogen receptor activation protects against TNF-α-induced endothelial dysfunction. Angiology (2013) 1.39
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Res (2007) 1.23
Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology (2005) 1.22
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle (2004) 1.22
Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J (2004) 1.21
Intrauterine fallopian tube incarceration after vacuum aspiration for pregnancy termination. Int J Gynaecol Obstet (2010) 1.19
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther (2011) 1.18
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res (2011) 1.16
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer (2010) 1.16
Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res (2008) 1.14
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics (2008) 1.14
To target or not to target, that is the question. J Clin Oncol (2013) 1.12
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter. Clin Cancer Res (2013) 1.12
Idiopathic central diabetes insipidus is associated with abnormal blood supply to the posterior pituitary gland caused by vascular impairment of the inferior hypophyseal artery system. J Clin Endocrinol Metab (2004) 1.10
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther (2002) 1.08
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res (2011) 1.07
Changes in interleukin-6 and IGF system and their relationships in placenta and cord blood in newborns with fetal growth restriction compared with controls. Eur J Endocrinol (2006) 1.04
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle (2003) 1.03
Menstrual pattern and menstrual disorders among adolescents: an update of the Italian data. Ital J Pediatr (2012) 1.02
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res (2008) 1.02
Generation and characterization of a mouse lymphatic endothelial cell line. Cell Tissue Res (2006) 1.02
Endocrine aspects of coeliac disease. J Pediatr Endocrinol Metab (2003) 1.01
Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res (2008) 1.00
Synchronous early-stage endometrial and ovarian cancer. Int J Gynaecol Obstet (2008) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res (2005) 1.00
Integration of hybrid single-photon emission computed tomography/computed tomography in the preoperative assessment of sentinel node in patients with cervical and endometrial cancer: our experience and literature review. Int J Gynecol Cancer (2012) 0.99
Embryo transfer following in vitro maturation and cryopreservation of oocytes recovered from antral follicles during conservative surgery for ovarian cancer. J Assist Reprod Genet (2012) 0.99
Update on age at menarche in Italy: toward the leveling off of the secular trend. J Adolesc Health (2009) 0.99
Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer (2014) 0.98
Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res (2003) 0.98
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Unique features of the mode of action of ET-743. Oncologist (2002) 0.97
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol (2010) 0.97
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol (2008) 0.97
Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease? Gynecol Oncol (2011) 0.97
Effect of starting xylose concentration on the microaerobic metabolism of Debaryomyces hansenii: the use of carbon material balances. Appl Biochem Biotechnol (2002) 0.96
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer (2009) 0.95
Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks. BMC Pediatr (2008) 0.95
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
p73: a chiaroscuro gene in cancer. Eur J Cancer (2007) 0.94
Locally relapsed and metastatic uterine leiomyoma: a case report. J Med Case Rep (2008) 0.93
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging (2006) 0.93
18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol (2012) 0.93
Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle (2004) 0.92
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther (2012) 0.92
Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy. J Med Virol (2009) 0.92
European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res (2002) 0.92